FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049885783> ?p ?o ?g. }

• W2049885783 endingPage "1085" @default.
• W2049885783 startingPage "1085" @default.
• W2049885783 abstract "4618 The concept of non-neuronal Acethlycholine synthesis and non-neuronal cholinergic system activity is longstanding. It was reported that nicotine in human NSCLC A549 cell line, via linking to alpha7-nicotinic receptors, potently induces Bad phosphorylation that is associated with reduced apoptotic cell death ( Jen et al. J Biol Chem. 2004; 279:23837 ). We have reported that mesothelioma cell growth is modulated by the cholinergic system in which agonists (i.e. nicotine) has a proliferative and anti-apoptotic effect and antagonists (i.e. curare) has an inhibitory and pro-apoptotic effect ( Trombino et al. Cancer Res. 2004; 64:135 ). Our objective, in this study, is to inhibit NSCLC & mesothelioma (A549, IST-MES2 cell lines & primary cell cultures obtained by human biopsies) cell growth in culture and in i.p.or ortotopically xenotransplanted SCID mice using a potent and specific antagonist of alpha-7-nicotinic receptor namely: alpha-Cobratoxin (alpha-CbT). Alpha-CbT, a member of the long alpha-neurotoxin family, is obtained from the venom of Naja naja kaouthia and 95% purified. We confirmed the presence of nicotinic receptors in all cells studied. Alpha-CbT is cytotoxic and induced apoptosis both in NSCLC and in mesothelioma cells.10 x IC 50 [10 nM] alpha-CbT, on A549 cells, induced reduction of mitochondrial membrane potential, release of cytochrome c and SMAC proteins, translocation of Bad to mitochondria, inhibition of BAD phosphorilation in Ser 112 and 136, dissociation of the complex BAD-14-3-3 and consequent formation of the complex BAD-BCL-XL and finally cleavage of caspase 9 and 3. This concentration induced mitotic catastrophe and destroyed tubulin arrangement. In SCID mice model the concentrations of 3.0 nM (1/ 3 in vitro IC 50 ), given three times a week for two months (i.p. or i.v.), did not induce lethality, net body weight loss or any signs of stress (i.e. lethargy, ruffled coat, ataxia). Furthermore 3.0 nM alpha-CbT did not change hematological parameters & levels of serum liver enzymes. Histology of several organs (i.e. brain, liver, heart, kidney, spleen, testis) appeared normal. 3.0 nM, as well as 1.0 nM (1/10 in vitro IC 50 ), alpha-CbT reduced, significantly, the tumor mass, induced “in vivo” apoptosis and decreased, significantly, the number of liver metastases. Cells, obtained after enzymatic digestion of tumors obtained from treated mice, showed high degree of apoptosis, low number of mitotic cells, are unable to clone in soft agar and to develop tumor when re-injected in SCID mice. Modified alpha-CbT (substitution in 33 R/E, not specific to nicotinic receptor) is ineffective. Interestingly, human proliferating T lymphocytes were not affected by alpha-CbT, also when treated at very high concentrations (1 microM). Cells without alpha-7-nicotinic receptors (Jurkat) are also not affected. In conclusion alpha-CbT shows clear and specific antitumor activity both in NSCLC and mesothelioma cells." @default.
• W2049885783 created "2016-06-24" @default.
• W2049885783 creator A5001478500 @default.
• W2049885783 creator A5012661742 @default.
• W2049885783 creator A5015582246 @default.
• W2049885783 creator A5017059477 @default.
• W2049885783 creator A5020903010 @default.
• W2049885783 creator A5027704478 @default.
• W2049885783 creator A5047297921 @default.
• W2049885783 creator A5047911191 @default.
• W2049885783 creator A5057339533 @default.
• W2049885783 creator A5059218575 @default.
• W2049885783 creator A5059916807 @default.
• W2049885783 creator A5062834268 @default.
• W2049885783 creator A5077518546 @default.
• W2049885783 creator A5078111994 @default.
• W2049885783 creator A5088106992 @default.
• W2049885783 date "2006-04-15" @default.
• W2049885783 modified "2023-09-26" @default.
• W2049885783 title "Development of novel therapeutic strategies for lung cancer: targeting the cholinergic system" @default.
• W2049885783 hasPublicationYear "2006" @default.
• W2049885783 type Work @default.
• W2049885783 sameAs 2049885783 @default.
• W2049885783 citedByCount "0" @default.
• W2049885783 crossrefType "journal-article" @default.
• W2049885783 hasAuthorship W2049885783A5001478500 @default.
• W2049885783 hasAuthorship W2049885783A5012661742 @default.
• W2049885783 hasAuthorship W2049885783A5015582246 @default.
• W2049885783 hasAuthorship W2049885783A5017059477 @default.
• W2049885783 hasAuthorship W2049885783A5020903010 @default.
• W2049885783 hasAuthorship W2049885783A5027704478 @default.
• W2049885783 hasAuthorship W2049885783A5047297921 @default.
• W2049885783 hasAuthorship W2049885783A5047911191 @default.
• W2049885783 hasAuthorship W2049885783A5057339533 @default.
• W2049885783 hasAuthorship W2049885783A5059218575 @default.
• W2049885783 hasAuthorship W2049885783A5059916807 @default.
• W2049885783 hasAuthorship W2049885783A5062834268 @default.
• W2049885783 hasAuthorship W2049885783A5077518546 @default.
• W2049885783 hasAuthorship W2049885783A5078111994 @default.
• W2049885783 hasAuthorship W2049885783A5088106992 @default.
• W2049885783 hasConcept C153911025 @default.
• W2049885783 hasConcept C170493617 @default.
• W2049885783 hasConcept C185592680 @default.
• W2049885783 hasConcept C190283241 @default.
• W2049885783 hasConcept C31573885 @default.
• W2049885783 hasConcept C502942594 @default.
• W2049885783 hasConcept C54355233 @default.
• W2049885783 hasConcept C55493867 @default.
• W2049885783 hasConcept C62112901 @default.
• W2049885783 hasConcept C81729549 @default.
• W2049885783 hasConcept C81885089 @default.
• W2049885783 hasConcept C86803240 @default.
• W2049885783 hasConcept C95444343 @default.
• W2049885783 hasConcept C98274493 @default.
• W2049885783 hasConceptScore W2049885783C153911025 @default.
• W2049885783 hasConceptScore W2049885783C170493617 @default.
• W2049885783 hasConceptScore W2049885783C185592680 @default.
• W2049885783 hasConceptScore W2049885783C190283241 @default.
• W2049885783 hasConceptScore W2049885783C31573885 @default.
• W2049885783 hasConceptScore W2049885783C502942594 @default.
• W2049885783 hasConceptScore W2049885783C54355233 @default.
• W2049885783 hasConceptScore W2049885783C55493867 @default.
• W2049885783 hasConceptScore W2049885783C62112901 @default.
• W2049885783 hasConceptScore W2049885783C81729549 @default.
• W2049885783 hasConceptScore W2049885783C81885089 @default.
• W2049885783 hasConceptScore W2049885783C86803240 @default.
• W2049885783 hasConceptScore W2049885783C95444343 @default.
• W2049885783 hasConceptScore W2049885783C98274493 @default.
• W2049885783 hasLocation W20498857831 @default.
• W2049885783 hasOpenAccess W2049885783 @default.
• W2049885783 hasPrimaryLocation W20498857831 @default.
• W2049885783 hasRelatedWork W1859740466 @default.
• W2049885783 hasRelatedWork W1975213794 @default.
• W2049885783 hasRelatedWork W1983333762 @default.
• W2049885783 hasRelatedWork W1996917088 @default.
• W2049885783 hasRelatedWork W2052171236 @default.
• W2049885783 hasRelatedWork W2052417990 @default.
• W2049885783 hasRelatedWork W2079900709 @default.
• W2049885783 hasRelatedWork W2085860355 @default.
• W2049885783 hasRelatedWork W2086217382 @default.
• W2049885783 hasRelatedWork W2147542603 @default.
• W2049885783 hasRelatedWork W2409360168 @default.
• W2049885783 hasRelatedWork W2516238729 @default.
• W2049885783 hasRelatedWork W2586315047 @default.
• W2049885783 hasRelatedWork W2597852296 @default.
• W2049885783 hasRelatedWork W2809739285 @default.
• W2049885783 hasRelatedWork W2810445747 @default.
• W2049885783 hasRelatedWork W281610513 @default.
• W2049885783 hasRelatedWork W2914316727 @default.
• W2049885783 hasRelatedWork W865362875 @default.
• W2049885783 hasRelatedWork W1875058116 @default.
• W2049885783 hasVolume "66" @default.
• W2049885783 isParatext "false" @default.
• W2049885783 isRetracted "false" @default.
• W2049885783 magId "2049885783" @default.
• W2049885783 workType "article" @default.